Overview

• Katie Price announced that her son Harvey will begin Mounjaro (tirzepatide) therapy under NHS England’s expanded community prescribing guidelines.
• Harvey, who has ADHD, autism, Prader-Willi syndrome, and septo-optic dysplasia, will move from his residential college into a Southampton independent living facility tailored to his needs.
• Mounjaro was approved by NICE in 2024 for NHS obesity treatment and became available to GPs for severely obese patients with comorbidities in June 2025.
• Price expects the weight loss to ease Harvey’s breathlessness and enable greater independence in daily activities.
• Dr Claire Fuller of NHS England said the community-based rollout will broaden access to obesity treatment for around 1.5 million eligible patients.